R03BA02 - Budesonide

Not porphyrinogenic

Rationale

Inducer of CYP3A5. Probably quantitatively insignificant metabolic exposure. Several references stating non-porphyrinogenicity of glucocorticoids. Significant clinical experience of non-porphyrinogenicity.

Chemical description

Corticosteroide in inhalation aerosol (50 µg/dose), used in treatment of asthma. Systemic bioavailability about 26%. Metabolised by CYP3A4.

Personal communication

Andersson C, patient reports: Tolerated (n=8). Used in porphyria ward (Sweden).

IPNet drug reports

Uneventful use reported in 21 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes R03B / R03BA or go back.

References

#	Citation details	PubMed ID
1.	Management of acute attacks in the porphyrias. Kalman DR, Bonkovsky HL. Clin Dermatol. 1998; 16(2):299-306.	9554242
2.	Drugs in the acute porphyrias--toxicogenetic diseases. Moore MR, Hift RJ. Cell Mol Biol (Noisy-le-grand). 1997 Feb; 43(1):89-94.	9074793
Porphyria Drug Lists
3.	EPI List European Porphyria Initiative No longer maintained
4.	South African List Porphyria South Africa No longer maintained
Other sources
5.	Porphyrin metabolism and the Porphyrias [Book Chapter] Tschudy DP, Lamon JM Bondy BK, Rosenberg LE (eds): Duncan's Diseases of Metabolism, Philadelphia, WB Saunders. 1980.